Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: